Abbott Laboratories (ABT) Continued Sixth Straight Quarter of Double-Digit Gains

Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a fall in equities, while fixed income benefited from perceived safety. The fund ended the quarter up 0.04%. The fund outperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), down 1.48%, and the Morningstar Moderate Allocation peer group, which fell 0.34%. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its first-quarter 2025 investor letter, Mairs & Power Balanced Fund highlighted stocks such as Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a leading manufacturer of health care products. The one-month return of Abbott Laboratories (NYSE:ABT) was 4.74%, and its shares gained 26.80% of their value over the last 52 weeks. On May 6, 2025, Abbott Laboratories (NYSE:ABT) stock closed at $133.06 per share with a market capitalization of $231.503 billion.

Mairs & Power Balanced Fund stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q1 2025 investor letter:

"The Fund’s overweight to the Health Care sector significantly contributed to relative outperformance which was further aided by positive selection within the sector. Abbott Laboratories (NYSE:ABT), a long-term portfolio holding, had its sixth quarter in a row of double-digit organic growth, while the market is increasingly appreciating the new trajectory for the diversified healthcare company."

Abbott Laboratories (NYSE:ABT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the fourth quarter, compared to 63 in the third quarter. While we acknowledge the potential of Abbott Laboratories (NYSE:ABT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we covered Abbott Laboratories (NYSE:ABT) and shared the list of stocks Jim Cramer talked recently. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.